Skip to main content
Clinical Trials/CTRI/2021/11/038260
CTRI/2021/11/038260
Not yet recruiting
未知

Evaluating effect of Escitalopram and Desvenlafaxine on anxiety and BDNF level in depression with comorbid anxiety â?? An open label, randomized, parallel group, clinical study - NI

Dr Chaitali Chindhalore0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
Sponsor
Dr Chaitali Chindhalore
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Chaitali Chindhalore

Eligibility Criteria

Inclusion Criteria

  • 1\.Drug naïve patients of either gender having age between 18 to 70 years with a clinical diagnosis of depressive episode as per ICD 10 (F 32\)
  • 2\.Hamilton Scale of Rating Depression (HAM\-D) score \>20;
  • 3\.Baseline Hamilton Anxiety Rating Scale (HAM\-A) score \> 14

Exclusion Criteria

  • 1\.Subjects with other coexistent psychiatric disorders as described by ICD 10, (World Health Organization, 2008\)
  • 2\.Subjects on antianxiety medication within washout period
  • 3\.Use of psychoactive substances except tobacco and caffein
  • 4\.Concurrent debilitating illnesses like chronic renal failure, malignancy, cirrhosis etc
  • 5\.Subjects on drugs which are known to interact with the study medications
  • 6\.History of allergy to study medication
  • 7\.Lactating and pregnant women

Outcomes

Primary Outcomes

Not specified

Similar Trials